Drug Metabolism Handbook (PDF)

Preface. List of Contributors. Part I: Introduction. 1. Historical Perspective (Roberta S. King). 2. Factors Affecting Metabolism (Roberta S. King). 3. Biotransformation sin Drug Metabolism (Roberta S. King). 4.In Vivo Metabolite Kinetics (Zheng Yang). 5. Pharmacogenetics and Pharmacogenomics (Lilian G. Yengi). 6. Introduction to drug transporters (Louis Leung and Aram Oganesian). Part II: Technologies for In Vitro and In Vivo Studies. 7. Automated Drug Screening for ADMET Properties (Melvin Reichman and Helen Gill). 8. Mass Spectrometry (Thomas R. Sharp). 9. Approaches to Performing Metabolite Elucidation: One Key to Success in Drug Discovery and Development (Ala F. Nassar). 10. Structural Modifications of Drug Candidates: How Useful Are They in Improving Metabolic Stability of New Drugs? Part I: Enhancing Metabolic Stability (Ala F. Nassar). 11. Structural Modifications of Drug Candidates: How Useful Are They in Improving PK Parameters of New Drugs? Part II: Drug Design Strategies (Ala F. Nassar). 12. Minimizing the Potential for Drug bioactivation of drug Candidates to Success in Clinical Development (Ala F. Nassar). 13. Screening for reactive Metabolites Using Genotoxicity Arrays and Enzyme/DNA Biocolloids (James F. Rusling, Eli G. Hvastkovs, and John B. Schenkman). Part III: Drug Interactions. 14. Enzyme Inhibition (Paul F. Hellenberg). 15. Evaluating and Predicting Human Cytochrome P450 Enzyme Induction (Michael Sinz, Sean Kim, Stephen Ferguson, and Edward LeCluyse). 16. An Introduction to Metabolic Reaction Phenotyping (Carl D. Davis and A. David Rodrigues). 17. Nuclear receptor-Mediated Gene Regulation in Drug Metabolism (Hongbing Wang and Wen Xie). 18. Characterization of Cytochrome P450 Mechanism-Based Inhibition (Dan Rock and Larry C. Wienkers). 19. Clinical Drug-Drug Interactions. 20. Pharmaceutical Excipients in drug-Drug Interaction (Chuan Chen and Abu J. M. Sadeque). Part IV: Toxicity. 21. The Role of Drug Metabolism in Toxicity (Carl D. Davis and

Ala F. Nassar, PhD, provides technical and operational
leadership in characterizing in vitro and in vivo metabolites. His
research focuses on understanding how structure modification can
improve the ADME profile for new chemical entities as they advance
towards clinical candidacy. Recently, he identified and patented
pharmacologically active metabolites of Nexavar®. Dr. Nassar
serves on the Editorial Board of Drug Metabolism Letters and The
Open Drug Metabolism Journal and is also a reviewer for several
other journals.

Paul F. Hollenberg, PhD, is Maurice H. Seevers Collegiate
Professor and Chair of Pharmacologyat The University of Michigan.
His current research focuses on the relationship between
thestructures of the active sites of cytochrome P450s and their
catalytic function. Dr. Hollenbergwas cofounder and Associate
Editor of Chemical Research in Toxicology and has served onnumerous
editorial boards and review panels.

Joann Scatina, PhD, has over twenty-four years of drug
metabolism experience, and is currentlyVice President of the Drug
Metabolism Division, Drug Safety and Metabolism, for WyethResearch.
Dr. Scatina's research interests include identification of
metabolites, metabolicpathways and enzymes responsible, in vitro-in
vivo extrapolation, and prediction of druginteractions. She is a
member of the American Society for Pharmacology and
ExperimentalTherapeutics and the International Society for the
Study of Xenobiotics (ISSX) and is currentlyserving on the
Editorial Board of Drug Metabolism Reviews.

Dieses eBook können Sie uneingeschränkt auf allen Geräten der tolino Familie lesen. Zum Lesen auf sonstigen eReadern und am PC benötigen Sie eine Adobe ID.